[PubMed: 39279639] Becerril S, Frhbeck G
Taurine, glutathione and bioenergetics [PMID: 23392865] Laboratory literature summary: Taurine, glutathione and bioenergetics
What are some of the most promising, high-growth opportunities for the s-acetyl-l-glutathione market by type (97% purity, 98% purity, and others), application (health product raw materials, cosmetic raw materials, pharmaceutical raw materials, active pharmaceutical ingredient, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)
PMID: 39841962
GLP-1RAs have been proven to reduce the risk of major adverse cardiovascular events (MACE) occurrence, including death from cardiovascular causes, non-fatal myocardial infarction and non-fatal stroke, as well as all-cause mortality in T2DM and patients with obesity ( The glucocorticoid receptors are present in GLP-1-producing cells, and their activation diminishes the secretory responsiveness of these cells ( 4.1 Efficacy of GLP-1 receptor agonist therapy in SID Considering their beneficial effects on body weight, effective glycemic control, and low risk of hypoglycaemia, GLP-1 RAs may be suitable therapeutic options for SID and SIH, either as adjunctive therapy or as primary treatment